<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03793985</url>
  </required_header>
  <id_info>
    <org_study_id>152BE17006</org_study_id>
    <nct_id>NCT03793985</nct_id>
  </id_info>
  <brief_title>Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337</brief_title>
  <official_title>Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the pharmacokinetic characteristics and safety between CKD-391 tablet and D337, D337
      combination
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">November 13, 2018</completion_date>
  <primary_completion_date type="Actual">October 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0~72hours</time_frame>
    <description>To evaluate pharmacokinetic equivalence of experimental arm comparing Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0~72hours</time_frame>
    <description>To evaluate pharmacokinetic equivalence of experimental arm comparing AUCt</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>A (R+T+R+T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : R Period 2 : T Period 3 : R Period 4 : T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (T+R+T+R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 : T Period 2 : R Period 3 : T Period 4 : R</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T</intervention_name>
    <description>CKD-391 40/10mg</description>
    <arm_group_label>A (R+T+R+T)</arm_group_label>
    <arm_group_label>B (T+R+T+R)</arm_group_label>
    <other_name>Test Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R</intervention_name>
    <description>D086 and D337 co-administration</description>
    <arm_group_label>A (R+T+R+T)</arm_group_label>
    <arm_group_label>B (T+R+T+R)</arm_group_label>
    <other_name>Reference drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 aged and 45 aged in healthy male adult

          2. Over 50 kg, BMI between 18.0-29.0 kg/m2

          3. Subjects in good health as determined by physical exams and medical examinations. No
             congenital or chronic diseases and no abnormal signs determined by medical
             examinations.

          4. Not abnormal or not clinically significant lab values.

          5. Subjects who signed informed consent form with good understandings after explanations
             by investigators.

        Exclusion Criteria:

          1. No history or presence of clinically significant diseases.

          2. Subjects showing adverse reaction to investigational product

          3. Genetic problems in galactose intolerance, Lapp lactose deficiency, or
             glucose-galactose malabsorption.

          4. History of myopathy

          5. Subjects with abnormal lab values at least one below 1) AST or ALT&gt;2 fold of upper
             normal limit 2) Total bilirubin&gt;2 fold of upper normal limit 3) CK&gt;2 fold of upper
             normal limit 4) Estimated Glomerular filtration rate&lt;60mL/min/1.73m2

          6. Drink over 21 units/week (1 unit= 10g=12.5mL of pure alcohol) or unable to stop
             drinking during clinical trials

          7. Smoke over 10 cigarettes per day or unable to stop smoking

          8. Subjects who previously participated in other clinical trials within 90 days

          9. Subjects who donated whole blood within 60 days or donated component blood within 30
             days or received blood transfusion within 30 days

         10. Subjects who took any prescribed medications or oriental medicines within 14 days, or
             took any pharmacy medicines within 10 days.

         11. Taking medications which induce or block medication metabolism

         12. History of drug abuse

         13. Subjects who took any prescribed medications or oriental medicines within 14 days, or
             took any pharmacy medicines within 7 days.

         14. Disagree to contraception

         15. Subjects who are in any conditions impossible participating in the clinical trials
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>INHA University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>January 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

